Background {#Sec1}
==========

Perioperative complications are still relatively frequent in patients undergoing cardiac or non-cardiac surgery, and attempts to minimize complications and deaths are crucial. Pathophysiological mechanisms behind clinical complications may include inflammatory processes after surgery.

The knowledge of statin's pleiotropic and anti-inflammatory effects has led to consider perioperative statin a potential treatment able to modulate the clinical outcome after surgery \[[@CR1]\]. Previous studies suggested beneficial effects of perioperative statin therapy on postoperative outcome after high-risk non-cardiac surgery \[[@CR2]--[@CR4]\], with a previous meta-analysis advising that perioperative statin therapy decreases the perioperative incidence of mortality and myocardial infarction in this high-risk population \[[@CR5]\].

In contrast, growing evidences on perioperative statins administration in cardiac surgery suggested neutral or even detrimental effects. In facts, two large, high-quality, trials randomizing cardiac surgery patients to receive perioperative statin or placebo were recently published \[[@CR6], [@CR7]\]. Perioperative statins did not prevent postoperative atrial fibrillation or perioperative myocardial damage, but acute kidney injury (AKI) was more common in patients receiving statin. All this evidence supported a potential neutral or even negative effect of perioperative statin in cardiac surgery.

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to provide clinical guidance of administration of perioperative statin therapy in the perioperative period. We aimed to assess the effects on postoperative myocardial infarction, stroke, AKI, and mortality in adult cardiac and non-cardiac surgery in patients treated with perioperative statins.

Methods {#Sec2}
=======

We performed a systematic review and meta-analysis of RCTs, in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR8]\] and the Cochrane methodology \[[@CR9]\], and according to a pre-published protocol (PROSPERO database, CRD42018093997) \[[@CR10]\]. A PRISMA checklist is available in the supplement (eTable 1, Additional file [1](#MOESM1){ref-type="media"}). The authors had no conflicts of interests.

Search strategy {#Sec3}
---------------

Two trained investigators (AP and CS) independently searched PubMed, the Cochrane Central Register of clinical trials, and EMBASE (last updated on May 1, 2018) for appropriate articles. The search strategy for PubMed is reported in the supplement (eMethods 1, Additional file [1](#MOESM1){ref-type="media"}) and was designed to include any RCT ever published with perioperative statin therapy compared to control in adult humans undergoing surgery. In addition, we employed backward snowballing (i.e., scanning of references of pertinent articles). No language restriction was enforced.

Study selection {#Sec4}
---------------

References, obtained from database and literature searches, were examined first at an abstract level independently by 2 investigators (AP and CS), with eventual divergences resolved by consensus, and then, if potentially pertinent, were retrieved as complete articles. Eligible studies met the following PICOS criteria: (1) Population: adult cardiac and non-cardiac surgery patients; (2) Intervention: perioperative administration of statin therapy; (3) Comparison intervention: placebo or no active intervention as control; (4) Outcome: any outcome of the present systematic review (see below); (5) Study design: RCT. The exclusion criteria were: overlapping populations and pediatric studies. Two authors (AP and JP or AB) independently assessed selected studies for the analysis, with divergences resolved by consensus with a third author (GL).

Data abstraction and study endpoint {#Sec5}
-----------------------------------

Baseline characteristics, procedural, and outcome data were abstracted by one author (AP) extracted relevant information from each selected study, and these data were checked by a second author (JP or AB). Specifically, we extracted potential sources of significant clinical heterogeneity, such as study design, clinical setting/indication, statin dose, and control treatment, as well as primary study outcomes.

The per-protocol primary outcomes were: postoperative MI, postoperative stroke, postoperative AKI, and mortality at the longest follow-up available. Post hoc secondary outcomes were AKI requiring postoperative renal replacement therapy (RRT) and AKI not requiring RRT. The outcomes were reported as per-author definition. We extracted data following the intention-to-treat basis whenever possible. Corresponding authors of all eligible articles were contacted in case of missing data on outcomes of interest.

Risk of bias assessment {#Sec6}
-----------------------

We used the Cochrane methodology to evaluate the methodological quality of each included trial \[[@CR9]\]. Each trial was finally judged to be of low, unclear, or high risk of bias (eMethods 2, Additional file [1](#MOESM1){ref-type="media"}). Publication bias was assessed by visually inspecting funnel plots for pooled analyses containing \> 10 studies \[[@CR9]\].

Statistical analysis {#Sec7}
--------------------

The analysis was stratified according to cardiac or non-cardiac surgery setting. For each outcome, we calculated the odds ratio (OR) with 95% confidence intervals (CI). For common events, pre-defined as frequency of the event in the control group \> 10%, we calculated risk ratio (RR) with 95% CI \[[@CR9]\]. A *p* value equal or less than 0.05 was considered significant. In case of statistical significant results, we calculated the number needed to treat (NNT) or number needed to harm (NNH) and 95% CI. Heterogeneity was explored by the Cochran *Q* statistic and characterized with *I*^2^. We used a fixed-effects model in the absence of significant heterogeneity, defined as *p* value \> 0.10 and *I*^2^ \< 50%. In case of significant heterogeneity, we employed the random-effects model except if few trials dominate the available evidence or if significant publication bias was present, since random-effects meta-analysis, in these contexts, can give inappropriate high weight to smaller studies \[[@CR9]\].

According to Cochrane methodology \[[@CR9]\], we performed subgroup analyses for each outcome in order to assess the influence of trials' risk of bias, including only low risk of bias trials or only trials with unclear or high risk of bias. Sensitivity analyses were performed changing summary statistic (OR, RR, risk difference) and according to possible conflicts of interests/funding. Meta-regression was employed to examine the possible influence of statin therapy regimen on clinical outcomes. Subgroup analyses were performed on trials that included only statin-naïve patients or trials not employing only statin-naïve patients (trials enrolling a population of chronic statin therapy or a mixed population). Subgroup differences were tested using Chi-square statistics \[[@CR9]\]. The meta-analysis was performed using Review Manager (RevMan \[Computer program\], version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). All the analyses were pre-defined \[[@CR10]\].

Trial sequential analysis {#Sec8}
-------------------------

To control risks of random errors due to sparse data and repetitive testing of cumulative data, we performed a per-protocol fixed-effects trial sequential analysis (TSA). TSA is a methodology that combines an information size calculation, representative of the cumulated sample sizes of all included trials, with a threshold for a statistically significant treatment effect and a threshold for futility of the intervention. In particular, TSA pools the required information size with trial sequential monitoring boundaries which adjust the confidence intervals and decrease type I errors \[[@CR11]--[@CR13]\]. In TSA, the inclusion of each trial in the meta-analysis is regarded as an interim meta-analysis and TSA permits to control the risk for type I and type II errors and helps to clarify whether additional trials are needed. Conclusions made using TSA show the potential to be more consistent than those using traditional meta-analysis techniques \[[@CR11]--[@CR13]\]. We conducted TSA with the purpose to maintain an overall 5% risk of type I error and a 10% risk of type II error, at a power of 90%. We assumed a relative risk reduction (RRR) or relative risk increase (RRI) of 15%, and we derived the control event proportion from low risk of bias trial. The resulting required information size was further diversity (*D*^2^)-adjusted; in case of *D*^2^ = 0, we performed a sensitivity analysis assuming a *D*^2^ = 25%. We used the TSA software (TSA Viewer \[Computer program\], version 0.9.5.5 Beta, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, 2016).

Results {#Sec9}
=======

Study characteristics {#Sec10}
---------------------

The literature search yielded 8376 references of which 35 RCTs (8200 randomized patients) \[[@CR2], [@CR3], [@CR6], [@CR7], [@CR14]--[@CR44]\] met the eligibility criteria and were included in the analysis (Fig. [1](#Fig1){ref-type="fig"}). Major exclusions are presented in the supplement (eTable 2, Additional file [1](#MOESM1){ref-type="media"}). Characteristics of the included trials are reported in Table [1](#Tab1){ref-type="table"} and in eTable 3 in the Additional file [1](#MOESM1){ref-type="media"}.Fig. 1Study flow diagram Table 1Characteristics of the trials included in the analysisTrialJournalSurgical procedureNumber of patientsStatinStatin regimenControlPatients naïve to statin therapy (%)Outcomes for meta-analysisRisk of bias*Cardiac surgery*Almansob 2012Arterioscler Thromb Vasc BiolNon-coronary cardiac surgery132Simvastatin 20 mg5--7 days pre-op and post-op day 2No treatmentnrMI, S, MHighAydin 2015Anatol J CardiolOn-pump CABG60Atorvastatin7 h post-op and 30 days post-opNo treatment100MI, MHighBaran 2011Stem Cell Rev and RepOn-pump CABG60Atorvastatin 40 mg14 days pre-op and post-op (no day 0)Placebo100AKI, MI, S, M, RRTHighBerkan 2008Thorac Cardiov SurgOn-pump CABG46Fluvastatin 80 mg3 weeks pre-opPlacebo100MIHighBillings 2016JAMAOn-/Off-pump cardiac surgery615Atorvastatin 40 mgBid day 1, qd day 0, and qd post-op^°^Placebo32AKI, MI, S, M, RRTLowCarrascal 2016Journal of ArrhythmiaValvular surgery90Atorvastatin 40 mg7 days pre-op and 7 days post-opNo treatment100AKI, MI, S, M, RRTHighCastaño 2015J Cardiovasc SurgOn-pump CABG30Pravastatin 40 or 80 mg2 h pre-opPlacebo0AKI, MI, S, M, RRTLowChello 2006Crit Care MedOn-pump CABG40Atorvastatin 20 mg3 weeks pre-opPlacebo100AKI, MI, S, MUnclearChristenson 1998Eur J Cardiothorac SurgOn-pump CABG77Simvastatin 20 mg4 weeks pre-opNo treatmentnrAKI, MI, MHighDehghani 2014J Cardiovasc Pharmacol TherValvular surgery58Atorvastatin 40 mg3 days pre-op and 5 days post-opPlacebo100MI, S, MHighHua 2017Biomed Res IntValvular surgery130Simvastatin 20 mg5--7 days pre-op and 7 days post-op (no days 0--1).Placebo100MHighJi 2009Circ JOff-pump CABG140Atorvastatin 20 mg7 days pre-opPlacebo100MI, S, MHighMannacio 2008J Thorac Cardiovasc SurgOn-pump CABG200Rosuvastatin 20 mg7 days pre-opPlacebo100AKI, MI, S, MHighMansour 2016Int J Adv BiomedCardiac surgery50Atorvastatin 40 mg7 days pre-op and post-opNo treatment100MI, S, MHighNakamura 2006CytokineOn-/Off-pump CABG31Atorvastatin 10 mgUnclearNo treatment32MUnclearPark 2016Intensive Care MedValvular surgery200Atorvastatin 40 mgBid day − 1 and qd days 0--1--2Placebo100AKI, MI, S, M, RRTLowPatti 2006CirculationOn-pump cardiac surgery200Atorvastatin 40 mg7 days pre-op and post-op until discharge (no day 0)Placebo100MI, MHighProwle 2012NephrologyOn-pump cardiac surgery100Atorvastatin 40 mgDays 0--1--2--3Placebo30AKI, M, RRTLowSong 2008Am Heart JOff-pump CABG124Atorvastatin 20 mg3 days pre-op and continued for 30 days post-opNo treatment100MI, SHighSpadaccio 2010J Cardiovasc PharmacolOn-pump CABG50Atorvastatin 20 mg3 weeks pre-opPlacebo100AKI, MI, S, MUnclearSun 2011Int Heart JOn-pump CABG100Atorvastatin 20 mg7 days pre-opPlacebo100MIHighTamayo 2009J Thorac Cardiovasc SurgOn-pump CABG44Simvastatin 20 mg3 weeks pre-opNo treatment100MHighVukovic 2010PerfusionOn-pump CABG57Atorvastatin 20 mg3 weeks pre-opPlacebo100MI, MHighYoun 2011Korean J Thorac Cardiovasc SurgOff-pump CABG142Rosuvastatin 40 mgBid day 1, qd day 0No treatment45MI, MHighZheng 2016N Engl J MedOn--/Off-pump CABG/AVR/CABG + AVR1922Rosuvastatin 20 mg1--8 days pre-op and 5 days post-opPlacebo66AKI, MI, S, M, RRTLow*Non*-*cardiac surgery*Amar 2015J Thorac Cardiovasc SurgPulmonary resection88Atorvastatin 40 mg7 days pre-op and 7 days post-opPlacebo100MI, MHighBass 2018HSSJHip fracture and total hip/knee replacement surgery20Atorvastatin 40 mg4 days pre-op and 45 days post-opPlacebo100AKI, MI, S, MHighBerwanger 2017Am Heart JNon-cardiac surgery in high-risk patients^a^642Atorvastatin 80 mg1 day pre-op and seven days post-opPlacebo100AKI, MI, S, MHighDurazzo 2004J Vasc SurgAortic, femoropopliteal, and carotid vascular surgery100Atorvastatin 20 mgAt least 14 days pre-op and up to 4 weeks post-opPlacebo100MI, S, MLowNeilipovitz 2012Can J AnaesthNon-cardiac surgery in high-risk patients^b^76Atorvastatin 80 mg7 days pre-op and 7 days post-op or day 0 and 7 days post-opPlacebo100MI, S, MHighParepa 2017FarmaciaElective non-cardiac, non- vascular surgery without known cardiac disease1380Rosuvastatin 10 mg10 days pre-op and 20 days post-opPlacebo100MI, MHighShyamsundar 2014Annals of SurgeryEsophagectomy31Simvastatin 80 mg4 days pre-op and 7 days post-opPlacebo100AKI, MI, S, MUnclearSingh 2016J Am Coll SurgColorectal resection or reversal of Hartmann's procedure surgery132Simvastatin 40 mg3--7 days pre-op and 14 days post-opPlacebo100MLowXia 2014CardiologyUrgent abdominal surgery^c^ in patients with stable CAD500Atorvastatin 80 mg2 h before surgeryPlacebo0MI, MLowXia 2015CardiologyUrgent abdominal surgery^c^ in patients with stable CAD550Rosuvastatin 20 mg2 h before surgeryPlacebo0MI, S, MUnclearAKI, acute kidney injury; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CAD, coronary artery disease; M, mortality; MI, myocardial infarction; RRT, renal replacement therapy; nr, not reported; pre-op, pre-operatively; post-op, post-operatively; day 0, the morning of the day of surgery; qd, once a day; bid, twice a day; °, patients on chronic statin therapy received study drug only on day 0 and day 1, resuming chronic statin therapy on postoperative day 2^a^Defined as: history of CAD, peripheral vascular disease, stroke, major vascular surgery, or any 3 of 7 risk factors criteria (intrathoracic or intraperitoneal surgery, congestive heart failure, transient ischemic attack, diabetes, renal failure, age \> 70 years, or emergent/urgent surgery)^b^Defined as: history of CAD, peripheral vascular disease, stroke, or congestive heart failure, or three of six risk factor (high-risk surgery, previous congestive heart failure, diabetes, renal failure, age \> 70 years, previous transient ischemic attack)^c^Acute suppurative appendicitis, acute cholecystitis, acute cholangitis, acute pancreatitis, peptic ulcer perforation or urinary calculi

Twenty-five trials (4698 patients) included elective cardiac surgery patients, with coronary artery bypass grafting surgery as the most represented procedure, performed in 72.29% of the patients. Ten trials (3502 patients) were performed in non-cardiac surgery setting \[[@CR2], [@CR3], [@CR17], [@CR19], [@CR29], [@CR33], [@CR34], [@CR39], [@CR41], [@CR43]\], in particular: 2 in elective non-cardiac surgery, 2 trials in elective vascular surgery, 1 in elective lung resection surgery, 1 in elective orthopedic surgery, 1 in elective esophagectomy, 1 in elective colorectal surgery, and 2 in urgent abdominal surgery.

Twenty-four trails included exclusively statin-naïve patients (4101 patients), 3 trials included patients on chronic statin therapy (1080 patients), and 5 trials had a mixed population (2810 patients). All trials administered statins preoperatively and 19 trials postoperatively. Length of preoperative statin treatment ranged from 1 to 28 days (median 7 days), and the total duration of therapy varied from 2 to 45 days (median 7 days). Atorvastatin (10--80 mg) was administered in 22 trials, simvastatin (20--80 mg) in 6 trials, rosuvastatin (10 and 20 mg) in 5 trials, pravastatin (40 or 80 mg) in 1 trial, and fluvastatin 80 mg in 1 trial. Twenty-six trials administered placebo as control, and 9 trials administered no intervention as control.

Eight trials were judged to be at low risk of bias in all bias domains \[[@CR3], [@CR6], [@CR7], [@CR21], [@CR30], [@CR32], [@CR34], [@CR39]\]. Five trials scored unclear-risk of bias \[[@CR22], [@CR33], [@CR35], [@CR43], [@CR44]\], and 22 trials were at high risk of bias (Fig. [2](#Fig2){ref-type="fig"} and eFigure 1, Additional file [1](#MOESM1){ref-type="media"}). No publication bias was found (eFigure 2--5, Additional file [1](#MOESM1){ref-type="media"}). Sensitivity analysis according to conflicts of interest or funding was consistent with primary analysis (eResults 1, Additional file [1](#MOESM1){ref-type="media"}).Fig. 2Risk of bias summary: review authors' judgments about each risk of bias item for each included study

In 13 cases, we received further outcomes' data from the authors \[[@CR6], [@CR14], [@CR17], [@CR19]--[@CR22], [@CR24], [@CR27], [@CR30], [@CR32]--[@CR34]\].

Myocardial infarction {#Sec11}
---------------------

The rate of postoperative MI was lower in non-cardiac surgery patients randomized to statins (OR = 0.44 \[95% CI 0.30--0.64\], NNT = 36 \[95% CI 25--66\]). However, TSA was not conclusive for a RRR = 15% (OR = 0.44 \[TSA-adjusted 95% CI 0.16--1.19\], 18.27% of the information size accrued) suggesting the need of further trials for a firm conclusion (eFigure 6, Additional file [1](#MOESM1){ref-type="media"}). The results were similar when limiting the analysis to low risk of bias trials (OR = 0.28 \[95% CI 0.13--0.64\], 2 trials and 300 patients) and at sensitivity analyses (eTables 4 and 5, Additional file [1](#MOESM1){ref-type="media"}).

In contrast, no beneficial effects related to statin administration were found in cardiac surgery (OR = 0.93 \[95% CI 0.70--1.24\], TSA inconclusive) (*p*~subgroup~ = 0.002) (Fig. [3](#Fig3){ref-type="fig"}), with results consistent at secondary analyses (eTables 4 and 5, Additional file [1](#MOESM1){ref-type="media"}).Fig. 3Postoperative myocardial infarction (MI). Forest plot for postoperative MI in patients with perioperative statin therapy versus control

Stroke {#Sec12}
------

No significant difference in postoperative stroke rate was found neither in cardiac surgery (OR = 1.10 \[95% CI 0.60--2.03\]) nor in non-cardiac surgery (OR = 0.71 \[95% CI 0.09--5.64\]) (Fig. [4](#Fig4){ref-type="fig"}), with TSA inconclusive and similar results at secondary analyses (eTable 4, Additional file [1](#MOESM1){ref-type="media"}).Fig. 4Postoperative stroke. Forest plot for postoperative stroke in patients with perioperative statin therapy versus control

Acute kidney injury and renal replacement therapy {#Sec13}
-------------------------------------------------

Perioperative statins were associated with higher incidence of AKI when compared to control in cardiac surgery patients (11 trials and 3384 patients, RR = 1.15 \[95% CI 1.00--1.31\], NNH = 40 \[95% CI NNH = 19 to NNT = 866\]) (Fig. [5](#Fig5){ref-type="fig"}), also when limiting the analysis to low risk of bias trials (1.17 \[95% CI 1.02--1.34\], NNH = 30 \[95% CI 16--307\]) (eTable 4, Additional file [1](#MOESM1){ref-type="media"}). At sensitivity analysis, the effect was not evident when employing a random-effects model (all trials: RR = 1.05 \[95% CI 0.85--1.30\]) or when limiting the analysis to statin-naïve patients (RR = 1.09 \[95% CI 0.75--1.57\]). Trial sequential analysis was inconclusive for a RRI = 15% due to the too small cumulative information size (eTable 4, Additional file [1](#MOESM1){ref-type="media"}).Fig. 5Postoperative acute kidney injury (AKI). Forest plot for postoperative AKI in patients with perioperative statin therapy versus control

No significant effect was found in non-cardiac surgery population (RR = 1.52 \[95% CI 0.71--3.26\], TSA inconclusive) (Fig. [4](#Fig4){ref-type="fig"}), but only 3 trials (239 patients) reported the outcome, with all the events coming from 1 trial \[[@CR19]\].

In cardiac surgery, no significant difference in postoperative RRT was found (OR = 1.46 \[95% CI 0.75--2.81\]), while AKI not requiring RRT was higher in the statin group (OR = 1.22 \[95% CI 1.02--1.46\]) (*p*~groups~ = 0.61) (eTable 4, Additional file [1](#MOESM1){ref-type="media"}). No trials performed in non-cardiac surgery reported these outcomes.

Mortality {#Sec14}
---------

The administration of perioperative statin therapy was associated with no significant difference in mortality in both study population, at a median follow-up of 30-days (Fig. [6](#Fig6){ref-type="fig"}). However, when assessing only lower risk of bias trials, perioperative statins were associated with increased mortality in the cardiac surgery population (OR = 3.71 \[95% CI 1.03--13.34\], NNH = 181 \[95% CI 97--1187\]) (eTable 4, Additional file [1](#MOESM1){ref-type="media"}). Trial sequential analysis suggested no firm evidence for a RRI = 15% and the need of further randomized trials.Fig. 6Postoperative mortality. Forest plot for postoperative short-term mortality in patients with perioperative statin therapy versus control (the longest follow-up available, median 30 days)

Clinical outcomes and statin regimen {#Sec15}
------------------------------------

In statin-naïve patients undergoing cardiac surgery, perioperative statins are associated with no significant differences in all the assessed outcomes (eTable 6, Additional file [1](#MOESM1){ref-type="media"}). Trials enrolling chronic statin users or a mixed population showed that perioperative statins are associated with a higher risk of AKI in cardiac surgery (RR = 1.16 \[95% CI 1.00--1.34\]) and no differences in other outcomes (eTable 6, Additional file [1](#MOESM1){ref-type="media"}).

In non-cardiac surgery, lower myocardial infarction is evident in both statin-naïve (OR = 0.49 \[95% CI 0.30--0.81\]) and chronic statin patients (OR = 0.37 \[95% CI 0.21--0.67\]), and no differences in other outcomes (eTable 6, Additional file [1](#MOESM1){ref-type="media"}). No significant between-groups differences were found between statin-naïve trials and other trials enrolling patients on chronic statin therapy or a mixed population (*p*~groups~ \> 0.05) (eTable 6, Additional file [1](#MOESM1){ref-type="media"}).

Meta-regression analysis failed to find possible relationships between length of pre- or postoperative statin regimen and clinical outcomes (eResults 2, Additional file [1](#MOESM1){ref-type="media"}).

Discussion {#Sec16}
==========

Our systematic review and meta-analysis suggests that perioperative statin therapy could be protective against postoperative myocardial infarction in non-cardiac surgery but associated with an increased risk of acute kidney injury in cardiac surgery. Statins were associated with an increase in hospital mortality in cardiac surgery in low risk of bias trials. However, the quality and quantity of randomized evidence are still insufficient to allow a firm conclusion on the topic.

This is the largest and most comprehensive meta-analysis of RCTs of statins in surgery performed so far, including 35 randomized trials and 8200 patients, evaluating the effect of statin therapy on outcomes in both non-cardiac and cardiac surgery using separate analysis. In non-cardiac surgery, a previous meta-analysis that evaluated 5 RCTs in vascular surgery did not show any detrimental or favorable effect of statins on postoperative outcomes \[[@CR45]\]. De Waal et al., in a meta-analysis of 16 trials, only included statin-naïve patients undergoing surgery and showed that starting statin therapy, in this cohort of patients who were not already on long-term statin treatment, reduces perioperative mortality, myocardial infarction, atrial fibrillation, and decreases length of hospital stay \[[@CR5]\]. Our study is consistent with previous findings regarding prevention in postoperative myocardial infarction, but we failed to find any other possible beneficial effects, even in the statin-naïve subgroup. On the other hand, a recent meta-analysis evaluated 23 trials in cardiac surgery and showed no effect of statin on postoperative incidence of myocardial infarction, infection, stroke, and atrial fibrillation, and a higher occurrence of AKI \[[@CR46]\].

A potential beneficial effect of perioperative statins on postoperative MI in non-cardiac surgery was found, in contraposition to the lack of effects in cardiac surgery patients. Regarding non-cardiac surgery, a randomized study suggested that a short-term treatment with atorvastatin significantly reduces the incidence of major adverse cardiovascular events after vascular surgery \[[@CR2]\]. In contrast, a more recent and larger trial found neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve non-cardiac surgery patients, even in the vascular surgery subgroup \[[@CR19]\]. Chopra and colleagues, in a meta-analysis published in 2012 including 15 RCTs with 2292 patients undergoing cardiac and non-cardiac surgeries, found that perioperative statin treatment reduced the risk of myocardial infarction \[[@CR4]\]. Nowadays, the growing quality and quantity of data can allow a more thoughtful analysis, confirming the potential benefits of statin in non-cardiac surgery in terms of MI prevention, but not in cardiac surgery. In fact, in the largest RCTs performed so far in cardiac surgery patients, no difference was found in postoperative MI and myocardial injury \[[@CR6], [@CR7]\]. Perioperative myocardial ischemia in non-cardiac surgery occurs mostly as consequence of endogenous catecholamine release and acute inflammatory response, resulting in an increased oxygen demand, heart rate, and contractility. Inflammation also leads to changes in atheromatous plaque features, culminating in the rupture of lipid-laden vulnerable lesions, thrombocytes activation with development of platelet-rich thrombi, acute vessel occlusion, and ischemia \[[@CR47], [@CR48]\]. Perioperative statins might reduce the risk of perioperative infarction due to its properties of endothelial modulation resulting in vasodilation in addition to its anti-inflammatory effects, reducing plaque instability \[[@CR49]\]. In cardiac surgery, myocardial infarction occurs mainly due to an ischemic event arising from either a failure in graft function, an acute coronary event involving the native coronary arteries, or inadequate cardioprotection during cardiopulmonary bypass. We might postulate that the different pathophysiology mechanisms could explain our findings of no protection of statins against MI after cardiac surgery. In addition, our findings showed no effect of perioperative statin in postoperative stroke, another crucial cardiovascular complication. However, further investigations are warranted in patients at high risk of cerebrovascular events.

Our systematic review, including 25 studies in cardiac surgery, of whom 5 with low risk of bias, confirms the previous findings of possible negative effects of statins on renal function of cardiac surgery patients. For many years, perioperative statins were considered an attractive therapy for preventing AKI following cardiac surgery, hypothesis based mainly on the positive results from retrospective series or high risk of bias RCTs \[[@CR50]\]. Nowadays, high-quality RCTs support the lack of a kidney-protective effect \[[@CR6], [@CR7], [@CR30]\]. The largest RCT showed that rosuvastatin therapy resulted in a significantly higher rate of AKI and plasma creatinine compared to placebo at 48 h after cardiac surgery \[[@CR7]\]. Similarly, the second largest RCT published so far showed a non-significant trend in favor of placebo and a possible harmful effect of perioperative statins in the small subgroup of statin-naïve patients with chronic kidney disease \[[@CR6]\]. The exact mechanisms of increased occurrence of AKI related to statin use need to be elucidated. There are possible effects of statin in kidney function, including mitochondrial dysfunction leading to overall cellular energy imbalance \[[@CR50]--[@CR52]\]. Further research is needed, especially in the non-cardiac surgery setting, where evidence is still limited, not allowing any conclusion on possible renal effects of statin in this population.

Strengths and limitations {#Sec17}
-------------------------

Our study has some limitations, which most of them are characteristics of all aggregate data meta-analyses \[[@CR53]\]. Different statin dosages and formulations were used as statin therapy in the included studies. We did not perform subgroup analysis of different types of perioperative statin regimens, since most of the trials administered different statin dose and formulation for different length of time, and the analysis would be underpowered and mainly driven by results of small and higher risk of bias trials. Another limitation is that only few high-quality randomized trials have been published so far in non-cardiac surgery setting. To assess the effects of methodological biases on results \[[@CR54]\], we assessed subgroup analyses according to trial risk of bias. A major strength of this meta-analysis is that we assessed the most important clinical outcome, mortality. We decided not to assess surrogate outcomes commonly related to statin administration, such as myalgia or creatinine kinase elevation, due to the heterogeneity in definitions and spurious reporting. Finally, most of the included trials were focused on perioperative period and did not report clinical outcomes at longer follow-up.

Further high-quality trials should systematically evaluate the relationship between postoperative outcomes and patients' variables (e.g., statin-naïve, chronic kidney disease), to the surgery, and to the statin regimen (e.g., therapy duration).

Conclusions {#Sec18}
===========

Our results suggest that perioperative statins appear to be protective against postoperative myocardial infarction in non-cardiac surgery and associated with an increased risk of acute kidney injury in cardiac surgery. There are still insufficient randomized data for firm conclusions on perioperative statin therapy, and possible positive or even negative effects on mortality could not be excluded. No randomized evidence supports the systematic administration of statins in surgical patients, especially in statin-naïve patients. Further RCTs should evaluate the safety profile, possible beneficial effects on patients' outcome, particularly in non-cardiac surgery, and assess the more appropriate time-point for eventual statin discontinuation before surgery in patients under chronic statin therapy.
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 {#Sec19}
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